Lupin Ltd has entered into Deed of Assignment with Boehringer Ingelheim International GmbH for the acquisition of brands Ondero and Ondero - Met (including trademark rights associated with the brands), which will enable the Company to provide comprehensive and best-in-class treatment options for diabetes management.

The brands relate to medicines for the diabetic segment. Value creation is expected for Lupin's diabetic portfolio.

The cash consideration for the above acquisition will be Euro 26 million.